Thomas Powles

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles et al. · Nature · 2018 · 5.5K citations

Life Sciences, Immunology, Oncology +16

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell et al. · The Lancet Oncology · 2017 · 1.3K citations

Medicine, Oncology, Pharmacology +12

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

Thomas Powles, Peter H. O’Donnell, Christophe Massard et al. · JAMA Oncology · 2017 · 846 citations

Medicine, Oncology, Pharmacotherapy +17

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

Alison Birtle, Mark Johnson, John Chester et al. · The Lancet · 2020 · 527 citations · Full text

Medicine, Oncology, Urology +15

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

F. Stephen Hodi, Marcus Ballinger, Benjamin Lyons et al. · Journal of Clinical Oncology · 2018 · 374 citations

Medicine, Immunology, Oncology +14